Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

DB:2TZ Stock Report

Market Cap: €2.8b

Tianjin Pharmaceutical Da Ren Tang Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure2.7yrs
Board average tenure3yrs

Recent management updates

Recent updates


CEO

Tianjin Pharmaceutical Da Ren Tang Group has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Jian Ma
Chief Financial Officer1.4yrsCN¥190.30kno data
Hong Zhou
Deputy GM5.6yrsCN¥1.38m0.0031%
€ 87.4k
Min Guo
Executive Directorno datano datano data
Yu Zhang
Chief Manufacturing Officer2.7yrsCN¥893.80kno data
Mingjie Shang
Executive Directorless than a yearCN¥299.00kno data
Yan Jiao
Secretary to the Board of Directors17yrsCN¥445.80k0.0013%
€ 37.3k

2.7yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 2TZ's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Hong Zhou
Deputy GM5.6yrsCN¥1.38m0.0031%
€ 87.4k
Min Guo
Executive Director3.4yrsno datano data
Mingjie Shang
Executive Director1.5yrsCN¥299.00kno data
Yoke Pheng Liew
Independent & Non-Executive Director4.5yrsCN¥259.16kno data
Lei Wang
Chairman of the Board2yrsCN¥2.63mno data
Yuanxia Wang
Chairman of Board of Supervisors5yrsno datano data
Jianhua Xing
Supervisor3yrsno datano data
Mingrui Zhang
Non-Executive & Non-Independent Director3yrsno datano data
Weiwen Mao
Non-Executive Non-Independent Director2yrsno datano data
Guat Kwang Yeo
Lead Independent Director1.1yrsno datano data
Ming Zhong
Independent Directorless than a yearno datano data

3.0yrs

Average Tenure

53yo

Average Age

Experienced Board: 2TZ's board of directors are considered experienced (3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yalei YanBohai Securities Co., Ltd.
Chengzhi ChenCGS International
Shanshan LiChina Merchants Securities Co. Ltd.